Edwards Lifesciences (EW) Downgraded by Northland Securities

Edwards Lifesciences (NYSE:EW) was downgraded by equities research analysts at Northland Securities from an “outperform” rating to a “market perform” rating in a research report issued on Wednesday, The Fly reports.

A number of other research firms also recently weighed in on EW. Cowen reaffirmed a “buy” rating and set a $165.00 price target on shares of Edwards Lifesciences in a research note on Tuesday, March 20th. SunTrust Banks reaffirmed a “buy” rating and set a $180.00 price target on shares of Edwards Lifesciences in a research note on Tuesday, April 10th. Zacks Investment Research downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th. Barclays raised their target price on shares of Edwards Lifesciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Finally, Morgan Stanley raised their target price on shares of Edwards Lifesciences from $130.00 to $138.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Five equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $145.92.

NYSE:EW opened at $134.67 on Wednesday. The company has a current ratio of 1.80, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15. The company has a market cap of $28,813.15, a price-to-earnings ratio of 35.44, a P/E/G ratio of 2.01 and a beta of 0.58. Edwards Lifesciences has a fifty-two week low of $97.70 and a fifty-two week high of $143.22.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, April 24th. The medical research company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.11. The company had revenue of $938.00 million for the quarter, compared to the consensus estimate of $936.69 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. Edwards Lifesciences’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.94 earnings per share. equities analysts predict that Edwards Lifesciences will post 4.52 earnings per share for the current fiscal year.

In related news, Director William J. Phd Link sold 12,000 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $122.24, for a total transaction of $1,466,880.00. Following the completion of the sale, the director now directly owns 24,596 shares of the company’s stock, valued at approximately $3,006,615.04. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Robert W.A. Sellers sold 12,020 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $131.03, for a total transaction of $1,574,980.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 197,236 shares of company stock valued at $26,488,281. Company insiders own 1.84% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Spectrum Asset Management Inc. NB CA grew its holdings in Edwards Lifesciences by 7.4% during the 4th quarter. Spectrum Asset Management Inc. NB CA now owns 5,795 shares of the medical research company’s stock valued at $653,000 after purchasing an additional 400 shares in the last quarter. LS Investment Advisors LLC grew its holdings in Edwards Lifesciences by 6.0% during the 4th quarter. LS Investment Advisors LLC now owns 7,789 shares of the medical research company’s stock worth $878,000 after acquiring an additional 440 shares in the last quarter. Resources Investment Advisors Inc. grew its holdings in Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock worth $132,000 after acquiring an additional 465 shares in the last quarter. Park Avenue Securities LLC grew its holdings in Edwards Lifesciences by 16.5% during the 4th quarter. Park Avenue Securities LLC now owns 3,548 shares of the medical research company’s stock worth $396,000 after acquiring an additional 503 shares in the last quarter. Finally, Creative Planning grew its holdings in Edwards Lifesciences by 1.7% during the 4th quarter. Creative Planning now owns 33,354 shares of the medical research company’s stock worth $3,759,000 after acquiring an additional 573 shares in the last quarter. 83.02% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/25/edwards-lifesciences-ew-downgraded-by-northland-securities.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

The Fly

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply